R D Carvajal
Overview
Explore the profile of R D Carvajal including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
195
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Piperno-Neumann S, Carlino M, Boni V, Loirat D, Speetjens F, Park J, et al.
Br J Cancer
. 2023 Jan;
128(6):1040-1051.
PMID: 36624219
Background: Up to 50% of patients with uveal melanoma develop metastases (MUM) with a poor prognosis and median overall survival of approximately 1 year. Methods: This phase I study evaluated...
2.
Dimitriou F, Namikawa K, Reijers I, Buchbinder E, Soon J, Zaremba A, et al.
Ann Oncol
. 2022 Jun;
33(9):968-980.
PMID: 35716907
Background: Mucosal melanoma (MM) is a rare melanoma subtype with distinct biology and poor prognosis. Data on the efficacy of immune checkpoint inhibitors (ICIs) are limited. We determined the efficacy...
3.
Yang J, Lagana S, Saenger Y, Carvajal R
J Immunother Cancer
. 2019 Nov;
7(1):310.
PMID: 31730503
Background: Eosinophilia has been reported as a rare, new biological effect of immune checkpoint inhibition that may be associated with improved treatment response and the development of immune-related adverse events....
4.
Guo J, Carvajal R, Dummer R, Hauschild A, Daud A, Bastian B, et al.
Ann Oncol
. 2017 Mar;
28(6):1380-1387.
PMID: 28327988
Background: The single-arm, phase II Tasigna Efficacy in Advanced Melanoma (TEAM) trial evaluated the KIT-selective tyrosine kinase inhibitor nilotinib in patients with KIT-mutated advanced melanoma without prior KIT inhibitor treatment....
5.
DAngelo S, Tap W, Schwartz G, Carvajal R
Sarcoma
. 2015 Jul;
2015:259817.
PMID: 26180507
[This corrects the article DOI: 10.1155/2014/391967.].
6.
DAngelo S, Tap W, Schwartz G, Carvajal R
Sarcoma
. 2014 Apr;
2014:391967.
PMID: 24778572
Sarcomas are heterogeneous malignant tumors of mesenchymal origin characterized by more than 100 distinct subtypes. Unfortunately, 25-50% of patients treated with initial curative intent will develop metastatic disease. In the...
7.
Ozao-Choy J, Carvajal R, Hamid O
Drugs Today (Barc)
. 2012 Jun;
48(6):381-93.
PMID: 22745924
Malignant melanoma is currently the fifth most common cancer in American men and the seventh most common in American women. Despite the advances made for early disease, the prognosis for...
8.
Shah G, Socci N, Gold J, Wolchok J, Carvajal R, Panageas K, et al.
Ann Oncol
. 2010 Jan;
21(8):1718-1722.
PMID: 20080829
Background: We treated melanoma patients with temozolomide (TMZ) in the neoadjuvant setting and collected cryopreserved tumor samples before and after treatment. The primary objective was to determine whether the response...
9.
Boss D, Schwartz G, Middleton M, Amakye D, Swaisland H, Midgley R, et al.
Ann Oncol
. 2009 Oct;
21(4):884-894.
PMID: 19825886
Background: AZD5438 is an orally bioavailable inhibitor of cyclin E-cdk2, cyclin A-cdk2 and cyclin B-cdk1 complexes. Three phase I studies assessed the clinical safety, tolerability, pharmacokinetics and pharmacodynamics of AZD5438...